HGSI Human Genome Sciences, Inc. (MM)

LONDON--GlaxoSmithKline PLC (GSK), a research-based pharmaceutical and healthcare company, said Friday it has completed its acquisition of Human Genome Sciences (HGSI) for 3.6 billion dollars on an equity basis, or $3 billion net of cash and debt.

MAIN FACTS:

-All outstanding shares of HGS were acquired for $14.25 per share in cash.

-Subsequent offering period for GSK's tender offer for HGS shares expired at 2100 GMT, on Aug. 2.

-Glaxo shares closed in London Thursday at 1487 pence valuing the company at 74.16 billion pounds.

-Write to Ian Walker at ian.walker@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires